Hormonal
Early combination therapy with new hypoglycemic drugs (SGLT-2i, GLP-1RA, or DPP-4i) achieves glycemic control faster and provides longer-lasting benefits compared to traditional stepwise monotherapy in prediabetes and type 2 diabetes.
If you have Type 2 Diabetes or prediabetes, starting with a combination of modern drugs (like SGLT-2 inhibitors, GLP-1 agonists, or DPP-4 inhibitors) alongside metformin is often more effective than starting with just one drug. This approach helps you reach healthy blood sugar levels faster and keeps them there longer, reducing the need to change treatments frequently. Discuss this strategy with your doctor to see if it fits your specific health profile and insurance coverage.
Clinical trials have show good glycemic control with combination therapy with new hypoglycemic drugs in prediabetes and T2DM (mostly traditional stepwise therapy), but early combination therapy appears to have faster, more, and longer-lasting benefits.
Why this rating
Supported by multiple randomized controlled trials (RCTs) and meta-analyses cited in the review.
Source
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Xiayun Ni et al. · Frontiers in Pharmacology · 2022
DOI 10.3389/fphar.2022.877797
More from this paper
- SGLT-2 inhibitors provide cardiovascular and renal protective benefits independent of their glucose-lowering effects, including reduced risk of heart failure hospitalization and worsening renal function.Strong
- GLP-1 receptor agonists provide significant cardiovascular benefits, including reduced risk of major adverse cardiovascular events (MACE) and stroke, in addition to weight loss and glycemic control.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →